使用慢性斑块牛皮的真实世界数据,对RISANKIZUMAB的药理动力学-药理学建模
Charlotte M Thomas1, Jessica Ruoheng Wei1, David Baudry1
1King's College London, London, UK.
British journal of clinical pharmacology
|February 15, 2026
概括
这项研究开发了一种药理动力学/药理动力学 (PK/PD) 模型,用于治疗牛皮的瑞桑基祖马布. 该模型可以帮助个性化剂量,以改善慢性斑块牛皮的治疗结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 皮肤病学 皮肤病学
- 数学建模的数学建模
背景情况:
- 慢性斑块牛皮是一种免疫介导的炎症性疾病.
- 瑞桑基祖马布是一种具有高成本和可变患者反应的生物治疗方法.
- 个性化剂量可以提高牛皮的治疗疗效.
研究的目的:
- 开发一个药理动力学/药理动力学 (PK/PD) 模型,用于risankizumab.
- 描述瑞桑基祖马布暴露与治疗反应之间的关系.
- 为了为牛皮患者提供个性化剂量策略.
主要方法:
- 使用真实世界的数据开发了一种序列性人群PK/PD模型.
- 数据包括序列药理动力学 (PK) 和牛皮区域和严重性指数 (PASI) 的测量.
- 描述PASI的最大效应周转模型,包括药物对病变发展的影响.
主要成果:
- 一个带有固定吸收率的单间PK模型描述了数据.
- 估计清除值为0.34L/天,分布体积为12.9L.
- 估计的关键参数包括基线PASI (23.4),EC50 (0.11 mg/L) 和Kout (0.05天-1).
结论:
- 药理学参数与risankizumab的临床试验数据保持一致.
- 该模型捕捉了牛皮病的疾病动态,适用于不同的药物.
- 这种PK/PD模型可以指导个性化的Risankizumab剂量,以优化牛皮治疗.
相关概念视频
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
17
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
17
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
18
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
18
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
21
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
21
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
17
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
17
01:14Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
17
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A...
17
01:12Analysis of Population Pharmacokinetic Data
822
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
822